Literature DB >> 8426573

Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?

L J Brandt1, V Broadbent.   

Abstract

Carboplatin is an effective chemotherapeutic agent against many solid tumours. Although it is thought to be less nephrotoxic than its precursor cisplatin, current paediatric treatment protocols require regular monitoring of renal glomerular function during and after carboplatin use. Because accurate assessment of renal function in children requires measurement of isotope-clearance glomerular filtration rates (GFRs), routine monitoring is costly and time consuming. We studied 26 paediatric patients who were receiving chemotherapy that included 500-600 mg/m2 of carboplatin per course. 51Cr-EDTA GFRs were measured initially and after one to seven courses (median four). There was no measurable difference between renal function before and after carboplatin (P = 0.8). Our study shows that routine monitoring of renal glomerular function is unnecessary. Carboplatin use in patients who have had unilateral nephrectomy as part of their treatment is also discussed. Paediatric oncology literature concerning nephrotoxicity and carboplatin is reviewed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426573     DOI: 10.1002/mpo.2950210107

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

1.  Langerhans cell histiocytosis--clinical and epidemiological aspects.

Authors:  V Broadbent; R M Egeler; M E Nesbit
Journal:  Br J Cancer Suppl       Date:  1994-09

Review 2.  Central nervous system disease in Langerhans cell histiocytosis.

Authors:  N Grois; Y Tsunematsu; A J Barkovich; B E Favara
Journal:  Br J Cancer Suppl       Date:  1994-09

3.  Dose-related nephrotoxicity of carboplatin in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

4.  Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab.

Authors:  Tomohiro Enokida; Shinya Suzuki; Tetsuro Wakasugi; Tomoko Yamazaki; Susumu Okano; Makoto Tahara
Journal:  Front Oncol       Date:  2016-09-14       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.